Zobrazeno 1 - 10
of 24
pro vyhledávání: '"John Beadle"'
Autor:
John Beadle, Peter Irwin
Publikováno v:
Microbiology Australia, Vol 43, Iss 4, Pp 156-159 (2022)
Canine monocytic ehrlichiosis (Ehrlichia canis infection) is a serious tick-transmitted disease of dogs that was considered exotic to Australia until recently. The disease was first reported across northern and central Australia in 2020, with signifi
Externí odkaz:
https://doaj.org/article/193072761938473cbfd989085f849e8d
Autor:
Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle, Emiliano Calvo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within
Externí odkaz:
https://doaj.org/article/26c0983875fa4d0da5e0fc2f0a11a2aa
Autor:
Richard Brown, John Beadle, Tom Lillie, Andrew Stone, Sarah Lockwood, Andrew Fox, Eirini Bournazou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/043682a7864d44ccb965414ce40f25e7
Autor:
Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, Ignacio Osman-Garcia, Luis Paz-Ares, Juan M. Bozada, Valentina Boni, Christine Blanc, Len Seymour, John Beadle, Simon Alvis, Brian Champion, Emiliano Calvo, Kerry Fisher
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-13 (2017)
Abstract Background Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in patients with resect
Externí odkaz:
https://doaj.org/article/5eba29bccc0b4a288d270633d6de56aa
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
Autor:
Sam Illingworth, Ying Di, Maxine Bauzon, Janet Lei, Margaret R. Duffy, Simon Alvis, Brian Champion, André Lieber, Terry Hermiston, Len W. Seymour, John Beadle, Kerry Fisher
Publikováno v:
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 62-74 (2017)
Enadenotucirev is an oncolytic group B adenovirus identified by a process of bio-selection for the ability to selectively propagate in and rapidly kill carcinoma cells. It is resistant to inactivation by human blood components, potentially enabling i
Externí odkaz:
https://doaj.org/article/a7c13d435d3b499f8c2068ee8f9375b9
Autor:
Arthur Dyer, Ying Di, Hugo Calderon, Sam Illingworth, Gray Kueberuwa, Alison Tedcastle, Phil Jakeman, Suet Lin Chia, Alice Brown, Michael A. Silva, David Barlow, John Beadle, Terry Hermiston, David J.P. Ferguson, Brian Champion, Kerry D. Fisher, Leonard W. Seymour
Publikováno v:
Molecular Therapy: Oncolytics, Vol 4, Iss C, Pp 18-30 (2017)
Enadenotucirev (EnAd) is a chimeric group B adenovirus isolated by bioselection from a library of adenovirus serotypes. It replicates selectively in and kills a diverse range of carcinoma cells, shows effective anticancer activity in preclinical syst
Externí odkaz:
https://doaj.org/article/002ab69ebda84c369b82dc56d1ee6d03
Autor:
Peter Irwin, John Beadle
Publikováno v:
Microbiology Australia. 43:156-159
Canine monocytic ehrlichiosis (Ehrlichia canis infection) is a serious tick-transmitted disease of dogs that was considered exotic to Australia until recently. The disease was first reported across northern and central Australia in 2020, with signifi
Autor:
John Beadle
Published in 1996: The Book the author produced, A Journall or Diary of a Thankfull Christian is essentially a manual, a how-to book about how to write a spiritual diary; moreover, it is the only one of its kind written in seventeenth-century England
Autor:
Richard Brown, Kumar Prabhash, Stephan von Haehling, John Beadle, Andrew J.S. Coats, Stefan D. Anker, Gwo Fuang Ho, Julia Tilson
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle
BACKGROUND: Cancer cachexia is a major cause of morbidity and mortality with no widely approved treatment. METHODS: The ACT-ONE trial is a randomized, double-blind, parallel group, placebo-controlled, phase II multicentre trial in patients (25-80 yea
Autor:
Ignacio Osman-García, Juan M. Bozada, Luis Paz-Ares, Ignacio Duran, Ramon Salazar, Kerry D. Fisher, C. Blanc, John Beadle, Rocio Garcia-Carbonero, Simon Alvis, Emiliano Calvo, Len Seymour, Valentina Boni, Brian R. Champion
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-13 (2017)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Journal for Immunotherapy of Cancer
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-13 (2017)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Journal for Immunotherapy of Cancer
Background Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in patients with resectable colo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b64ec435f83c1bb7e6e321babb5da060
https://hdl.handle.net/10668/11588
https://hdl.handle.net/10668/11588